Table 3.
Pathological results and tumor response to neoadjuvant treatment (N = 34)b
| No. (%) | |
|---|---|
| ypT | |
| 0 | 9 (26.4) |
| 1 | 0 (0) |
| 2 | 5 (14.7) |
| 3 | 17 (50.0) |
| 4 | 3 (8.9) |
| ypN | |
| 0 | 28 (82.4) |
| 1 | 5 (14.7) |
| 2 | 1 (2.9) |
| Median number of resected nodesa | 11 (3–26) |
| Median number of involved nodesa | 0 (0–6) |
| Lymph node with extranodal involvement | 4 (11.7) |
| Lymphovascular invasion | |
| Yes | 5 (14.7) |
| No | 29 (85.3) |
| Perineural invasion | |
| Yes | 2 (5.9) |
| No | 32 (94.1) |
| Tumor differentiation | |
| Well | 2 (5.9) |
| Moderately | 28 (82.4) |
| Poorly | 4 (11.7) |
| Resection margin (CRM) | |
| Negative | 31 (91.2) |
| Positive | 3 (8.8) |
| Pathologic complete response | |
| Yes | 9 (26.4) |
| No | 25 (73.6) |
| Tumor regression grade | |
| 0 | 9 (26.4) |
| 1 | 11 (32.4) |
| 2 | 7 (20.6) |
| 3 | 7 (20.6) |
| ypT0-2 vs. ypT3-4 | |
| ypT0-2 | 14 (41.2) |
| ypT3-4 | 20 (58.8) |
| Pathologic T stage | |
| Downstaging | 24 (70.6) |
| Stable | 10 (29.4) |
| Progressive | 0 (0) |
| Pathologic N stage | |
| Downstaging | 31 (91.2) |
| Stable | 3 (8.8) |
| Progressive | 0 (0) |
| Pathologic TN stage | |
| Downstaging | 29 (85.3) |
| Stable | 5 (14.7) |
| Progressive | 0 (0) |
aMedian (range)
bTwo patients (T4bN2M0 and T4aN2M0) did not receive surgical resection due to unresectable tumor despite chemoradiotherapy
ypT postoperative pathologic tumor stage, ypN postoperative pathologic nodal stage, CRM circuferential resection margin